Advancing vaccine-based immunotherapy in glioblastoma treatment

  • Desh Deepak Singh
  • , Shafiul Haque
  • , Abhishek Kumar Singh*
  • , Dharmendra Kumar Yadav*
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Glioblastomas (GBMs) originate from glial cells and are characterized by aggressive growth and poor prognosis. Despite advances in surgical resection, complete elimination remains challenging, often leading to recurrence that is resistant to standard therapies. Immunotherapy and conventional treatments show promise in enhancing therapeutic outcomes across various cancers. Researchers continue to explore new treatments, particularly radiation, chemotherapy, and surgery; however, glioblastoma remains highly challenging, with only modest improvements in survival. Recent progress in immunotherapy, especially with tumor vaccines such as peptide-based and cell-based options (eg, dendritic cell vaccines), represents significant advancements despite the limitations observed in current clinical trials.This article reviews recent developments in vaccine-based immunotherapy for glioblastoma treatment.

Original languageEnglish
Article numbervdaf135
JournalNeuro-Oncology Advances
Volume7
Issue number1
DOIs
Publication statusPublished - 01-01-2025

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Advancing vaccine-based immunotherapy in glioblastoma treatment'. Together they form a unique fingerprint.

Cite this